Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib + Gedatolisib in Advanced Solid Tumors
NCT03065062Phase 1Suspended
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2017
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of palbociclib and gedatolisib in squamous cell carcinoma of the lung (LSCC), pancreatic cancer (PC), head and neck cancer (HNC) and 1 more, sponsored by Dana-Farber Cancer Institute. Primary endpoints: Maximum Tolerated Dose and Recommended Phase 2 Dose at 2 years and Incidence of Treatment-Emergent Adverse Events at 2 years. Started Feb 2017; status: suspended.
02
Drugs
palbociclibgedatolisib
03
Conditions
squamous cell carcinoma of the lung (LSCC)pancreatic cancer (PC)head and neck cancer (HNC)solid tumor
Beyond the preview
Go deeper on NCT03065062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03065062.